masitinib (Pending FDA Approval)

Brand and Other Names:Masican
  • Print

Dosing & Uses

AdultPediatric

Amyotrophic Lateral Sclerosis

Pending FDA approval for amyotrophic lateral sclerosis (ALS)

Safety and efficacy not established

Next:

Pharmacology

Mechanism of Action

Oral stem cell factor (SCF) receptor tyrosine kinase inhibitor; targets mast cells and macrophages by inhibiting a number of protein kinases within these cells

Masitinib targets neurotoxic aberrant glial cells (resident macrophages in the brain) via CSF1R inhibition, thereby providing a neuroprotective effect and slowing down neurodegeneration

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.